Ambulantes Therapiezentrum


Lymphome

HD21 for advanced stages

Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms; Vergleich 6 Zyklen BEACOPPesk mit 6 Zyklen BrECADD

NIVEAU
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma

DADA
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse

Stand 04.03.2022